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Diarrhea is the manifestation of gastrointestinal infection and is one of the major causes
of mortality and morbidity specifically among the children of less than 5 years age
worldwide. Moreover, in recent years there has been a rise in the number of reports
of intestinal infections continuously in the industrialized world. These are largely related
to waterborne and food borne outbreaks. These occur by the pathogenesis of both
prokaryotic and eukaryotic organisms like bacteria and parasites. The parasitic intestinal
infection has remained mostly unexplored and under assessed in terms of therapeutic
development. The lack of new drugs and the risk of resistance have led us to carry out
this review on drug development for parasitic diarrheal diseases. The major focus has
been depicted on commercially available drugs, currently synthesized active heterocyclic
compounds and unique drug targets, that are vital for the existence and growth of
the parasites and can be further exploited for the search of therapeutically active
anti-parasitic agents.
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INTRODUCTION
Diarrhea is a symptom of an infection in the intestinal tract, which can be caused by variety of
bacterial, viral, and parasitic organisms. Infection spreads through contaminated food or drinking
water or from person to person as a result of poor hygiene. Diarrheal diseases is the second leading
cause of death in children under 5 years and is responsible for killing around 760,000 children
every year (World Health Organization, 2013). The common symptoms include the frequent bowel
movements, loose watery stool, incontinence, lower abdominal pain, or cramping and in severe
cases it causes blood or flecks of mucus in the stool. The dreadful infection leads to the loss of
appetite and patient is more likely to suffer from loss of weight. There are a number of non-
infectious medical conditions that may cause diarrhea too. The inability in digesting dairy products
which includes lactose intolerance, coeliac disease which is an intolerance of gluten in wheat and
some other grains and pancreatic problems (cystic fibrosis) which interfere with production of
important digestive substances (Haque et al., 2003). Several agents that cause diarrhea include
viruses (rotavirus or Norwalk virus, enterovirus, or a hepatitis virus), bacteria (Shigella species,
Escherichia coli, and Campylobacter jejuni) and parasites (Giardia lamblia, Entamoeba histolytica,
and Cryptosporidium species; Shah et al., 2009). Diarrhea caused by parasites is unlike that of either
bacterial or viral infections. For instance,Giardia has a slow onset of diarrhea and can be present for
months, while most bacterial and viral infections are limited to 1–2 weeks (Petri, 2003). In addition,
parasites are eukaryotic, whichmakes them larger andmore complex than either viruses or bacteria
and alsomore difficult to eradicate due to their similarity to the host. Though the infection is caused
by a number of parasites which mainly include G. lamblia, E. histolytica, Cryptosporidium parvum,
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Cyclospora cayetanensis, Isospora belli, Blastocystis hominis but
the enzyme immunoassays are only available for the testing of
three parasites G. lamblia, E. histolytica, and C. parvum (Slack,
2012).
Many of the new drug targets are being discovered with
much more ease as the genomic sequences of many parasitic
organisms are becoming available. This advancement has enabled
researchers not only to identify new biochemical pathways and
gene families that can be short-listed as potential drug targets
but also has significantly increased their basic understanding of
parasites that cause some of the most severe diseases. Moreover,
biochemical analysis and genome sequencing both have helped
in identifying potential targets, enzymes, transporters, and
metabolites that are distinct in parasites and their mammalian
host (Loftus et al., 2005). As a consequence one can design even
better and safer effective drugs that can be used in future to
combat the disease caused by the organism. The heterocyclic
compounds with different modifications have been synthesized
and their biological evaluation have identified them to fight
the diarrhea causing parasites. In the following discussion some
of the most important parasites causing diarrhea, their drugs,
important traced targets and the active heterocyclic compounds
synthesized against them have been summarized.
MICROSPORIDIA
Enterocytozoon bieneusi, Encephalitozoon cuniculi, and
Encephalitozoon intestinalis are the reported species of
microsporidia which are the causative agents of chronic
diarrhea predominantly in immunocompromised individuals
such as AIDS patients (Blanshard et al., 1992; Chokephaibulkit
et al., 2001; Goodgame, 2003). The diarrheal disease caused
by microsporodia spp. is treated by drugs fumagilin (1) and
albendazole (2) (Goodgame, 2003; Agholi et al., 2013). The
polyamine analogs, fumagillin-related compounds and analogs,
nikkomycins (3), fluoroquinolones (4–9) and benzimidazole-
related compounds are the active sources of new compounds
against microsporidiosis. Fumagillin, a natural product (1)
is an antibiotic and anti-angiogenic compound produced
by Aspergillus fumigatus and has been found potent against
Encephalitozoon spp. and E. bieneusi in vitro (Bacchi and
Weiss, 2004). The antimicrosporidial activity of various
fluoroquinolones derivatives such as norfloxacin (4) and
ofloxacin (5) is more than gatifloxacin (6), lomefloxacin (7),
moxifloxacin (8), and nalidixic acid (9) and can be the effective
option of chemotherapy (Didier et al., 2005). It was observed
that TNP-470 (10), ovalicin (11) and its derivatives inhibited
E. intestinalis replication by more than 70% in vitro which
indicates that these compounds can be used as medication for
this infection (Didier et al., 2006). It has been also reported
that the use of chlorine and ozone as disinfectants kills the E.
intestinalis in water (John et al., 2005).
The albendazole, a benzimidazole derivative inhibits the
microtubule assembly in E. intestinalis but not in E. bieneusi
infections because benzimidazoles bind to the colchicine-binding
site of β-tubulin monomer prior to dimerization with α-tubulin
which blocks subsequent microtubule formation (Macdonald
et al., 2004). The β-tubulin subunit is the primary target of
benzimidazole, where its predictive sensitive residues are Cys
165, Phe 167, Glu 198, Phe 200, Arg 242, and Val 268 (Macdonald
et al., 2004; Tremoulet et al., 2004). It has been also reported
that microtubule assembly gets inhibited due to the presence of
hydrogen atom at the 1-position and a methoxycarbonylamino
group at the 2-position of the benzimidazole ring (Friedman
and Platzer, 1980). Fumagillin along with its analogs act on the
methionine aminopeptidase type 2(MetAP2) by non-competitive
inhibition, i.e., by irreversibly blocking the active site in E.
cuniculi and it seems to be the potent inhibitor (Molina et al.,
2002). Analysis of EcMetAP2 demonstrated conservation of
the key residues associated with the active site of this class
of enzymes including Asp251, Asp262, His331, Glu364, and
Glu459 (involved in coordination of metal binding); His231
(to which fumagillin covalently binds); and Phe219, Leu328,
Ile338, His339, Asp378, Tyr444, Leu447 (involved in binding
substrates into the active site; Upadhya et al., 2006). The
aspartic proteases are a family of protease enzymes that use
two highly conserved aspartic acid residues in the active site for
catalytic cleavage of their peptide substrates (Pozio and Morales,
2005). Ritonavir (12) and indinavir (13) drugs are inhibitors
of aspartyl protease, used in the highly-active antiretroviral
therapy cocktail, inhibited the growth of E. intestinalis in tissue
culture due to intermolecular hydrogen bonding between -NH
group of these drugs with aspartic acid residue (Menotti et al.,
2005; Pozio and Morales, 2005). The polyamine analogs are
important as they act by causing depletion of polyamines, due
to excessive acetylation and excretion of intracellular amines,
followed by cytostasis, apoptosis and cell death (Bacchi et al.,
2001). In sporoblasts of E. cuniculi, the chitin deacetylase
activity (EcCDA) is present in the inner part of the cell wall
tightly associated with the plasma membrane. This location was
analyzed by biochemical and sequence data, and suggests a
role in cell-wall formation. Late sporogony was characterized
by the thickening of the chitin-containing endospore, but
the mechanism of chitin deposition is unknown. Since the
EcCDA enzyme is regularly distributed at the plasma membrane
throughout sporogony, chitin may be produced all around
the cell (Brosson et al., 2005). The chitin is potent target of
nikkomycins due to their deacetylation activity (Bacchi et al.,
2001). The fluoroquinolones interact with E. cuniculi targets
significantly with DNA topoisomerases, which are the enzymes
that have evolved to solve the topological problems associated
with DNA metabolisms such as transcription, replication,
packing and unpacking of DNA in the cell (Hooper, 2000).
So, present research studies are concentrating on compounds
that target microsporidian polyamines (e.g., polyamine analogs),
Chitin (e.g., nikkomycins), and DNA topoisomerases (e.g.,
fluoroquinolones; Bacchi et al., 2001; Zhang et al., 2005; Didier
and Weiss, 2006).
ENTAMOEBA HISTOLYTICA
E. histolytica is the causative agent of amoebiasis, a contagious
disease of the human gastrointestinal tract (Tengku and
Norhayati, 2011; Watanabe et al., 2011). It is an organism
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implicated in both diarrheal disease and invasive disease such
as liver abscesses. Metronidazole (14) is the first line medication
used against the infection but long-term uses produce several
side effects in patients (Ordaz-Pichardo et al., 2005). It is
potentially carcinogenic to humans because it is genotoxic to
human cells (Bendesky et al., 2002). Furthermore, resistance of
E. histolytica to standard drug metronidazole and relapses of
intestinal and hepatic amoebiasis have been reported (Becker
et al., 2011; Hwang et al., 2011). The authors have earlier
reported diverse functionalized organic compounds synthesized
and screened against E. histolytica (Azam and Agarwal, 2007,
2015). Nitroimidazole compounds have been used to treat
a number of anaerobic bacteria and pathogenic protozoan
infections, including Trichomonas vaginalis, E. histolytica, and
G. lamblia since decades (Müller, 1983; Upcroft et al., 1999).
Presently, metronidazole, tinidazole (15) and ornidazole (16)
are highly recommended drugs for the treatment of protozoal
infections (Azam and Agarwal, 2007). The interesting fact about
the metronidazole analogs as an alternative to the treatment of
parasitic infections is facilitated by the fact that not only the
metronidazole is an effective drug but it also has a side chain
which provides an opportunity to carry out various modifications
whose significant activity has been reported (Kucik et al., 2004).
Chalcones are the important class of antamoebic drugs and
their analogs have been synthesized having better activity. A
series of chalcones were synthesized bearing N-substituted
ethanamine by aldol condensation reaction and the compound
(17) was found to be very potent amoebicidal indicating that
such compounds can be the effective therapeutic candidates
(Zaidi et al., 2015). Metronidazole hydrazone conjugates were
synthesized and screened in vitro for antiamoebic activity,
the compound (18) was found more active (Ansari et al.,
2015). A series of chloroquinoline-acetamide hybrids were
synthesized and the compound (19) inhibit the growth of E.
histolytica (Inam et al., 2015). The N-acylhydrazones derived
from 7-chloro-4-piperazin-1-yl-quinoline were evaluated against
E. histolytica and the compound (20) was more potent than
metronidazole (Inam et al., 2014). Metronidazole-triazole
hybrids (21) showed amoebicidal activity (Negi et al., 2014).
Coordination complexes do exhibit the anti-amoebic activity and
the efficacy depends on the selection of both central metal atom
and ligands. The terpyridine ligand complexed with divalent
metals viz Cu, Co, Mn, Ni, and Zn yield the coordination
complexes of general formula [Metal(Fctpy)2][PF6]2. The
complex Ni(Fctpy)2][PF6]2 (22) has been found to be having
most promising activity against E. histolytica and therefore,
can be used as significant drug candidates for amoebiasis
(Juneja et al., 2014). Hydrazone and oxadiazoline derivatives
of 2-methyl-5-nitro-1H-imidazole were being synthesized and
evaluated in vitro against HM1:IMSS strain of E. histolytica and
it was observed that compounds (23, 24) were more potent
against amoebiasis (Wani et al., 2013). A series of pyrazoline
derivatives were synthesized and their in vitro screening
against HM1: IMSS strain of E. histolytica, results showed the
compounds (2E)-1,3-bis(4-methylphenyl)prop-2-en-1-one (25)
and 1-(4,5-dihydro-5-(4-methoxyphenyl)-3-phenylpyrazol-1-
yl)- 2-(5-(4-methoxyphenyl)-1H-tetrazol-1-yl)ethanone (26)
exhibited the excellent antiamoebic activity and were having
the IC50-values of 4.19 and 1.16µM, respectively (Wani et al.,
2012b). Compounds bearing a tetrazole and triazine ring motifs
in conjugation with a sulphonamide group were synthesized
and N, N/-6-(1,3-benzodioxol-5-yl)-(1,3,5-triazine-2,4-diyl)-
bis-4-nitrobenzene sulphonamide (27) was found to be more
potent antiamoebic in nature and was having IC50-value of
1.02µM (Wani et al., 2012a). The in vitro antiamoebic activity
of 4,6 aminopyrimidines and their sulphonamide derivatives
was investigated against E. histolytica and it was found that
the compound N-[4-(2-chlorophenyl)-6-phenylpyrimidin-2-
yl]-benzenesulphonamide (28) having IC50-value 0.44µM was
most active (Siddiqui and Azam, 2014). Various derivatives
of dioxazoles were synthesized and in vitro analysis showed
that the compound 5-(4-methoxy-phenyl)-3-(5-nitro-2-
thienyl)-1,4,2-dioxazole (29) was having IC50-value 1.60µM
and inhibited the growth of E. histolytica significantly (Irfan
et al., 2010). Thiosemicarbazides are the focused moieties
for antiamoebic drug synthesis and the attempt was made
to synthesize a novel series of 4-substituted 1-{[4-(10,15,20-
triphenylporphyrin-5-yl)phenyl]methylidene}thiosemicarbazide
and their antiamoebic activity was investigated. The 4-(3-
methylphenyl)-1-{[4-(10,15,20-triphenylporphyrin-5-yl)phenyl]
methylidene}thiosemicarbazide (30) with an electron-
withdrawing group attached to N(4) exhibited the best
antiamoebic activity and was having IC50-value 0.538µM (Bhat
et al., 2008). A new series of thiosemicarbazones of 7-hydroxy-
8-acetylcoumarin with different thiosemicarbazides were
synthesized and were tested against E. histolytica. The 7-hydroxy-
8-acetylcoumarin-N(4,4)methylbenzyl thiosemicarbazone (31)
was having IC50-value 1.06µM and found to be antiamoebic
(Iqbal et al., 2009). Thiocarbamoyl bis-pyrazoline derivatives
were synthesized by cyclization of chalcones with N-4 substituted
thiosemicarbazides under basic conditions and the evaluation
showed that the compound(4-nitrophenylamino)[5-(4-{1-[(4-
nitrophenylamino)thioxomethyl]-3-phenyl(2-pyrazoline-5-yl-
phenyl)}-3-phenyl(2-pyrazolinyl)]methane-1-thione (32) was
having IC50-value 0.42µM and predominantly active
as an amoebicidal candidate (Bhat et al., 2009a). An
attempt was made to synthesize the amino-5-substituted-
(3-phenyl(2-pyrazolinyl))methane-1-thione derivatives,
2-(5-substituted-3-phenyl-2-pyrazolinyl)-1,3-thiazolino[5,4-b]
quinoxaline derivatives, and various chalcones derivatives
for evaluation against HM1:IMSS strain of E. histolytica.
The quinoxaline2-{5-[2-(methylethyl)phenyl]-3-phenyl- 2-
pyrazolinyl}-1,3-thiazolino[5,4-b]quinoxaline (33) showed
most promising antiamoebic activity with IC50-value of
0.17µM. The results suggested that the further modification
of such compounds can enhance their efficacy (Budakoti
et al., 2009). The synthesis of bis-ferrocenyl-substituted core-
modified porphyrins derivatives were synthesized under acidic
conditions and their in vitro screening was performed against
HM1:IMSS strain of E. histolytica. The promising results showed
the1,1/-(10,15-diphenyl-21,23-dithiaporphine-5,20-diyl)bis[2-
{[methyl(phenylmethyl)amino]methyl}-ferrocene] (34) having
IC50-value of 0.59µM was extremely potent (Bhat et al., 2009b).
A library of isothiourea derivatives was synthesized and the
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maximum activity was shown by compound (35) with IC50-
value 2.48µM. These are the amphiphilic compounds and
exist in cationic form which makes them active in biological
systems (Kazimierczuk et al., 2010). Benzimidazoles proved to be
having antiparasitic activity and 5(6)-chloro-1H-benzimidazole-
2-(3H)-thione (36) was having IC50-value of 0.005µM for E.
histolytica which indicates that these derivatives are having
higher activity than metronidazole (Valdez et al., 2002). A series
of ethyl and methyl quinoxaline-7-carboxylate 1,4-di-N-oxide
derivatives were synthesized by Beirut reaction and evaluated
against HM1:IMSS strain of E. histolytica. The methyl 2-acetyl-3-
methyl-quinoxaline-7-carboxylate 1,4-di-N-oxide (37) and ethyl
2-amide-3-methylquinoxaline-7-carboxylate 1,4-di-N-oxide
(38) were having IC50-value 1.41 and 1.47µM, respectively and
showed higher potency toward amoebicidal activity (Duque-
Montaño et al., 2013). The benzologue derivative of nitazoxanide
2-{[(6-Nitro-1,3-benzothiazol-2-yl)amino]carbonyl}phenyl
acetate(39) having IC50-value 0.297µM showed better
antiamoebic activity as compared to metronidazole and
indicated that such derivatives can be explored for the search
of effective chemotherapy (Navarrete-Vazquez et al., 2011).
The amide derivatives of trifluoromethionine (TFM) have been
observed to have excellent activity against E. histolytica. Using
the TFM as lead 3,4-dimethoxyanilide trifluoromethionine (40)
with methoxy group at meta and para positions was having
IC50-value 1.19µM and was observed most active in vitro
evaluation (Sato et al., 2010). The compound 1,5-bis[4-(5-
methoxy-1H-benzimidazole-2-yl) phenoxy]pentane (41) was
evaluated in vitro against E. histolytica showed remarkable
IC50-value 0.109µM for amoebicidal potency due to methoxy
group attached to benzimidazole ring (Torres-Gomez et al.,
2008b). Acetamide and sulfonamide derivatives of imidazole
viz N-benzyl-2-(2-methyl-4-nitro-1H-imidazol-1-yl)acetamide
(42) and 2-methyl-1-[(4-methylphenyl)sulfonyl]-4-nitro-
1H-imidazole (43) are important class of antiparasitic
agents and were having IC50-value 3.96 and 3.55µM,
respectively (Hernández-Nunez et al., 2009). Phenyl hydrazine
derivatives were synthesized and it was observed that (E)-1-
(3-nitrobenzylidene)-2-phenylhydrazine (44) was most potent
against HM1:IMSS strain of E. histolytica in vitro having IC50-
value 0.84µM. This indicated that hydrazine derivatives can be
explored for the search of effective chemotherapeutic agent for
amoebiasis and their mechanism of action needs to be elucidated
(Toledano-Magana et al., 2015).
Emphasizing the elucidated drug targets and mechanism, the
mode of action of metronidazole lies in that it gets reduced to
nitroradical anion or nitrosoimidazole by thioredoxin reductase
(TrxR) inside E. histolytica cell (Leitsch et al., 2007). The
nitroradical anion formed reduces O2 and thereby generates
reactive oxygen species, which are highly noxious to the
cells of microaerophilic E. histolytica. However, the nitroso
imidazole reacts with non-protein thiols or proteins to forms
adduct. The adduct causes depletion of non-protein thiols and
the modification of thioredoxin reductase (TrxR), thioredoxin
(Trx), superoxide dismutase (SOD), metronidazole target protein
1 (Mtp1), and purine nucleoside phosphorylase (PNP). The
combination of proteins with activated metronidazole makes the
cells more vulnerable to oxidative stress and thereby kills E.
histolytica (Figure 1; Samarawickrema et al., 1997; Leitsch et al.,
2007). 5-Nitroimidazoles have been the mainstay of treatment,
but resistance is a concern and new drug targets are needed. One
potential target is the biosynthetic pathway for cysteine which
is crucial for growth and various cellular activities (Diamond
et al., 1978; Gilin and Diamond, 1980). Besides being precursor
for protein biosynthesis, cysteine may compensate for the lack
of glutathione, a major component of oxidative stress resistance
in many organisms (Fahey et al., 1984; Loftus et al., 2005).
It is also needed in the attachment to matrix, elongation and
mobility of E. histolytica cells (Gilin and Diamond, 1980). In
this organism, the condensation of O- acetylserine with sulfide
is the major route of cysteine biosynthesis, which involves two
key enzymes: O-acetyl-L-serine sulfhydrylase (OASS) and serine
acetyltransferase (SATase; Nozaki et al., 1998). In general, in
plants and most known organisms, the cysteine biosynthesis
pathway is regulated both by the interaction of SAT and OASS
to form the cysteine synthase complex (CSC) under sulfur
sufficient condition but this type of regulation is absent in E.
histolytica. These enzymes have been demonstrated to play a
central role in controlling the intracellular cysteine concentration
in E. Histolytica (Nozaki et al., 1999) and block of cysteine
biosynthesis is therefore a possible strategy for inhibiting growth
of E. histolytica (Ali and Nozaki, 2007). E. histolytica along
with a number of other parasitic protists utilizes an unusual
form of phosphofructo-1-kinase (PFK; EC 2.7.1.90) in a central
step in carbohydrate metabolism. A homology model of E.
histolytica PPi-PFK was constructed and screened with various
bisphosphonates, which are analogs of pyrophosphate with a
carbon instead of oxygen atom and synthetic pyrophosphate. It
was found that the Compounds BA49280E (45) and CGP42446A
(46) were good inhibitors of PFK in E. histolytica. Based on
this study it has been suggested that PFK is attractive target for
antiamoebic drugs (Reeves et al., 1974, 1976). Triosephosphate
isomerase is another relatively well-studied glycolytic enzyme
with both its sequence and structure known in a large number
of organisms including E. histolytica (Rodriguez-Romero et al.,
2002). It has been proposed to be a target for drug design due to
presence of a cysteine residue (Cys 14) at the dimer interface in
E. histolytica (Gómez-Puyou et al., 1995). Alcohol dehydrogenase
2 (EhADH2) is a bifunctionl 97 kDa polypeptide having the
alcohol and aldehyde (ALDH) dehydrogenase activities utilize
NAD and Fe2+ as cofactor (Bruchhaus and Tannich, 1994). This
enzyme does not have a homolog in man. However, E. histolytica
possesses other NADP dependent ADH and ALDH enzymes
that could serve a similar function i.e., EhADH1, EhADH3 and
EhALDH1. EhADH1 enzyme does not utilize acetyl CoA as
substrate thereby suggesting that EhADH2 is solely responsible
for the conversion of acetyl CoA to acetaldehyde (Zhang et al.,
1994). Based on this data it has been suggested that EhADH2
could also serve as a target for antiamoebic drugs. Calcium is
an important secondary messenger in many signal transduction
pathways, is thought to be involved in the pathogenesis of
amoebiasis and the prevention of the influx of Ca2+ can be
the potent target (Meza, 2000). In E. histolytica, a number of
calcium binding proteins have been identified. More importantly
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FIGURE 1 | Mode of action of metronidazole in E. histolytica.
two distinct calcium binding proteins EhCaBP1 and EhCaBP2,
have been characterized and their role has been simultaneously
approached (Sahoo et al., 2003). It has been characterized that
cyclosporine A inhibits calcineurin and P-glycoprotein activity
and thereby inhibits proliferation of E. histolytica (Carrero et al.,
2004). Recently it has been shown that when expression of
EhCaBP1(a calmodulin containing 134 amino acid long proteins
demonstrated to be essential for Entamoeba) is blocked, the
cellular proliferation in E. histolytica gets inhibited (Sahoo et al.,
2004).
GIARDIA LAMBLIA
G. lamblia, an amitochondriate parasite is the major causative
agent of human diarrheal disease, infecting an estimated 10%
of the world’s population both endemically and epidemically
(Huang and White, 2006). For the treatment of the intestinal
infections caused by G. lamblia at least six different classes
of drugs are used, but the drugs containing 5-nitroimidazole
moiety are most often prescribed due to their significant efficacy.
However, the other classes are used when the former fails
in treatment. Metronidazole (14), tinidazole (15), ornidazole
(16) and secnidazole (47) are the 5-nitroimidazole moiety
containing drugs. Furazolidone (48) a nitrofuran derivative,
albendazole (2) and mebendazole (49) the benzimidazole
derivatives, quinacrine (50) an acridine derivative, paromomycin
(51) an aminoglycoside derivative and nitazoxanide (52) a
5-nitrothiazolyl derivative are also used for the treatment of G.
lamblia diarrheal disease depending on the age of patient. But
these drugs have various side effects (Reynoldson et al., 1992;
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Escobedo and Cimerman, 2007). The in vivo effects of benzyl
and cyclohexyl derivatives like, 2-(1H-1-imidazolyl)-1-phenyl-
1-ethanol, 2-(2–methyl–1 H-1-imidazolyl)–1-phenyl-1-ethanol,
2-(2-methyl-4-nitro-1H-1-imidazolyl)-1-phenyl-1-ethanol, 2-
(1H-1-imidazolyl)-1-cyclohexanol and 1[bis-4-methoxyphenyl-
phenylmethyl]-2-methyl-4-nitroimidazole (53–57) were studied
on the G. lamblia trophozoite in the white Syrian mice model
and were found to be active (Motazedian et al., 2014). The
thieno[2,3-b]pyridine derivatives were synthesized and the
4-(4-methoxyphenylamino)thieno[2,3-b]pyridine-5-carbonitrile
having the –OCH3 group at para position (58) showed the
excellent giardicidal effect possibly due to the higher electron
density concentrated over phenyl ring (Bernardino et al., 2006).
A series of novel hybrids of benzimidazole-pentamidine
were prepared and 1,5-bis[2-methoxy-4-(5-methyl-1H-
benzimidazole-2-yl)phenoxy] pentane (59) was found 3-
and 9-folds more potent against G. lamblia infection than
metronidazole and pentamidine, respectively and was having
IC50-value of 0.372µM (Torres-Gomez et al., 2008a). The
2-(trifluoromethyl)benzimidazole derivatives like 5-chloro-
1-methyl-2-(trifluoromethyl)benzimidazole (60), differently
substituted at the 1-, 5-, and 6-positions proved to be active
against G. lamblia in their in vitro analysis and IC50-value of
0.042µM was observed for compound (60) (Gabriel Navarrete-
Vaa Zquez et al., 2001). A library of chalcones was prepared
by condensing substituted acetophenones with benzaldehydes
using the Claisen–Schmidt base-catalyzed aldol condensation
reaction. Among these chalcones, substituted with –OCH3,
-H, -Cl, -F at different positions (E)-3-(6-flourophenyl)-1-
(4-methoxyphenyl)prop-2-en 1-one (61) with IC50-value of
12.72µM showed the excellent results toward the giardial
infection (Montes-Avila et al., 2009). The benzimidazole
derivative 5(6)-chloro-1H-benzimidazole-2-(3H)-thione
(62) was reported active in vitro against G. lamblia with
IC50-value of 0.005µM and inhibits tubulin polymerization
(Valdez et al., 2002). The albendazole analogs 1-methyl-6-
(propylthio)-2-(trifluoromethyl)-1H-benzimidazole (63) and
5(6)-(propylthio) -2-(trifluoromethyl)-1H-benzimidazole (64)
were having IC50-values 1.403 and 1.515µM, respectively are
active toward giardiasis. The mebendazole analogs 5-benzoyl-
1-methyl-2-(trifluoromethyl)-1H-benzimidazole (65) and
6-benzoyl-1-methyl-2-(trifluoromethyl)-1H-benzimidazole (66)
have also been found to be active against G. lamblia
and these were having IC50-values 1.098µM 1.285µM,
respectively (Navarrete-Vazquez et al., 2003). Among
the series of 3-tetrazolylmethyl-4H-chromen-4-ones the
compound 3-((1-cyclohexyl-1H-tetrazol-5-yl)((3,4,5-
trimethoxyphenyl)amino)methyl)-4H-chromen-4-one (67)
having IC50-value of 171.4µM can represent the suitable
alternatives against resistant G. lamblia parasites(Cano
et al., 2014). Thiazole derivatives were synthesized
and screened against G. intestinalis, two novel methyl
5-nitro-1,3-thiazol-2-ylcarbamate (68) and ethyl [(5-nitro-
1,3-thiazol-2-yl)amino](oxo)acetate (69) proved to be
potent giardicidal and were having IC50-value of 0.010
and 6.410µM, respectively(Nava-Zuazo et al., 2014).
By using the Ugi-azide multicomponent reaction, novel
3-tetrazolylmethyl-4H-chromen-4-ones were synthesized
and evaluated against G. lamblia. The in vivo investigation
demonstrated that these compounds like (70) could be
specifically considered drug candidates for giardial infection
(Cano et al., 2014). A series of novel hybrids from benzimidazole
and pentamidine were prepared and tested in vitro against
the protozoa and it was observed that the compound1,5-
bis[2-methoxy-4-(5-methyl-1H-benzimidazole-2- yl)phenoxy]
pentane (71) with IC50-value 0.372µM showed 3- and 9-
fold more activity against G. lamblia than metronidazole
and pentamidine, respectively (Torres-Gomez et al., 2008b).
Benzologues of nitazoxanide and tizoxanide were synthesized
and tested in vitro against G. intestinalis. The 2-{[(6-nitro-
1,3-benzothiazol-2-yl)amino]carbonyl}phenyl acetate (39)
was having IC50-value 3.515µM and was18-times more
potent than metronidazole (Navarrete-Vazquez et al., 2011).
Acetamide derivatives of imidazole like N-(4-cyanophenyl)-
2-(2-methyl-4-nitro-1H-imidazol-1-yl) acetamide (72) and
2-methyl-4-nitro-1-[(4-nitrophenyl)sulfonyl]-1H-imidazole
(73) were screened in vitro and were found active against
G. lamblia with IC50-value 11.25 and 7.50µM, respectively.
These can be further modified to enhance their activity
(Hernández-Nunez et al., 2009).
Accentuating the targets, G. lamblia utilizes the arginine
dihydrolase pathway to produce ATP from ADP and L-
arginine (Schofield et al., 1990), a pathway which is lacking in
higher eukaryotes including humans. The arginine dihydrolase
pathway employs three enzymes, arginine deiminase, ornithine
transcarbamoylase, and carbamate kinase (CK; EC 2.7.2.2). CK
catalyzes the last step of the pathway, converting carbamoyl
phosphate and ADP into carbamate and ATP (Figure 2; Lim
et al., 2013). Carbamate kinase is essential enzyme of Giardia
lamblia, and the antialcoholism drug disulfiram (74) kills the
trophozoites and inhibits this enzyme. Disulfiram and their
analogs act by modifying Cys242 adjacent to the active site
and cure of giardiasis in mice has also been reported (Galkin
et al., 2014). Nitazoxanide, nitroimidazoles, metronidazole and
tinidazole use nitroreductases such as pyruvate ferredoxin
oxidoreductase (PFOR) as their target sites in Giardial infection
(Hoffman et al., 2007; Müller et al., 2007). The 5-nitroimidazoles
like metronidazole act in G. lamblia by two distinct mechanisms.
In one mechanism metronidazole gets reduced to toxic nitro-
radical anion via pyruvate ferredoxin oxidoreductase/ferredoxin
(PFOR/Fd) couple in presence of pyruvate and the cofactor
FIGURE 2 | Arginine dihydrolase pathway in G. lamblia.
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FIGURE 3 | Mode of action of nitroimidazoles in G. lamblia.
CoASH during the electron transport pathway in G. lamblia. In
the second mechanism metronidazole reduction occurs due to
the activity of G. lamblia thioredoxin reductase (GlTrxR). The
radicals formed cause oxidative damage to G. lamblia cell and
thereby kills parasite (Figure 3).
Protein disulfide isomerases, specifically PDI2 and PDI4 have
recently been reported as promising targets for new drugs
effective against giardiasis (Müller et al., 2007). Furazolidone gets
reduced by NADH oxidase when the reduced products obtained
disrupt the action of DNA in Giardial infection (Brown et al.,
1996; Upcroft and Upcroft, 1998). Recently, Hsp90 inhibitors
as potential leads for antiparasitic chemotherapy have been
reported. Hsp90 inhibitor prodrug (SNX-5422) was evaluated
in animal models to proof the principle that an oral drug
could be effective (Debnath et al., 2014). Metronidazole analogs
were more active than metronidazole in changing significantly
the morphology and ultrastructure of the parasite G. lamblia.
The analogs affected parasite cell vesicle trafficking, autophagy,
and triggered differentiation into cysts of G. lamblia (Busatti
et al., 2013). The novel nitroreductase target sites viz GlNR1
and GlNR2 have been identified to be the potent targets for
nitroimidazole, metronidazole, nitrothiazolide and nitazoxanide
in G. lamblia (Muller et al., 2015).
CRYPTOSPORIDIUM PARVUM
The protozoan C. parvum causes cryptosporidiosis which
is associated with watery diarrhea that may sometimes be
profuse and prolonged in children (Current and Garcia, 1991;
Bouzid et al., 2013). It is the second most common protozoan
pathogen responsible for severe diarrhea and was also associated
with death in young children under 12–23 months of age
(Kotloff et al., 2013). Currently nitazoxanide (52), paromomycin
(51), and azithromycin are the most commonly used for the
treatment of cryptosporidiosis. However, nitazoxanide (52)
is effective in the immunocompetent and ineffective in the
immunocompromised patients (Mead, 2002; Gargala, 2008).
The available medication is not effective in all the patients
besides having side effects of headache, nausea, stomach pain,
severe or persistent dizziness,shortness of breath and unusual
tiredness. Progress in the development of anti-cryptosporidial
drugs has been very slow due to the difficulty in the in vitro
culture of Cryptosporidium (Abrahamsen et al., 2004; Andrews
et al., 2014). Many drug targets are not present in this parasite
because it has completely lost the plastid derived apicoplast. Its
mitochondrion lacks the citrate cycle and cytochrome based
respiratory chain which directs the novel target identification
for drug development. Recently a research group synthesized
11 derivatives of benzimidazole, out of which three compounds
(75–77) showed anti-cryptosporidic effect equivalent to
paromomycin (Graczyk et al., 2011). The dicationic carbazole
compounds are active against C. parvum and compound (78)
was elucidated to be potent against cryptosporidiosis (Blagburn
et al., 1998). The macrolide antibiotics like spiramycin (79),
roxithromycin (80), and clarithromycin (81) were thought to be
promising drugs against cryptosporidiosis but the final clinical
trials have not yet been completed. There is the intense need for
the development of effective chemotherapy for cryptosporidiosis
in immunodeficient patients (Saez-Llorens, 1989; Uip et al.,
1998). The nitrogen-containing bisphosphonates (N-BPs)
exhibit anticryptosporiudium activities in low micromolar
concentrations. It has been observed that NBPs act on the
novel non-specific polyprenyl pyrophosphate synthase that can
synthesize isoprenoids from C20->C45 in Cryptosporidium spp
(Artz et al., 2008).
In C. parvum, phosphofructokinase enzyme is pyrophosphate
specific (PPi-PFK; Denton et al., 1996). The accepted dogma is
that PPi-PFK is advantageous to anaerobic organisms because
its economic effect on the cell’s consumption of ATP means
that the net production from glycolysis is three ATP molecules
per glucose molecule rather than the more usual two ATP
molecules (Coombs and Müller, 1995). The critical role played
by PPi-PFK in energy metabolism together with difference from
the human host PFK, make it an attractive target for drug. A
mannitol cycle is an important part of energy metabolism for C.
parvum. A key feature of the cycle is that the enzyme initiates
mannitol biosynthesis, mannitol-1-phosphate dehydrogenase, is
regulated by the binding of a specific inhibitor, a protein that
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has been found to belong to the 14–3–3 group of proteins.
Inhibition of mannitol synthesis would be likely to have a severe
impact upon the oocyst stage of the parasite and so reduces
transmission (Schmatz, 1997). The inosine-5′-monophosphate
dehydrogenase (IMPDH) and proteases are also proposed to
be the target sites in cryptosporidial infection (Mandapati
et al., 2014). It has a bacterial-type inosine-5′-monophosphate
dehydrogenase (IMPDH) as the only means to convert AMP to
GMP (Umejiego et al., 2008). The target site of the paromomycin
is the A site of ribosome where upon action it disrupts the
protein biosynthesis in C. parvum (Müller et al., 2007). Acyl-
coenzyme-A synthetases have been observed to be inhibited
by triacsin C in cryptosporidial infection in mice (Guo et al.,
2014). The dicationic-substituted aromatic molecules act by
binding to the minor groove of DNA in the Cryptosporidium and
thereby affects. DNA-associated enzymes such as topoisomerases,
endo and exonucleases or other processes, such as DNA
replication, recombination, and repair (Hildebrandt et al.,
1998). Mebendazole or albendazole acts by interacting with the
colchicine site of tubuline in themicrotubules ofCryptosporidium
spp (Brown et al., 1996).
BLASTOCYSTIS HOMINIS
Blastocystis hominis is a unicellular anaerobic protozoon and
infects the human gastrointestinal tract. It gets transmitted via
animal contact, water and food contaminated with excreted cysts
of the organism (Eroglu and Koltas, 2010). The pathogenesis of B.
hominis leads to symptoms such as diarrhea, flatulence, anorexia,
abdominal pain, vomiting, perianal pruritics, and bloating
(Sheehan et al., 1986; Chen et al., 2014). The currently used
drugs against this infection are metronidazole (14) or tinidazole
(15) (Sohail and Fischer, 2005; Tan, 2008). Metronidazole
commonly used for the treatment of blastocystosis induces
programmed cell death in the B. hominis(Nasirudeen et al.,
2004). The reduction of the nitro group cytotoxic radicals in
mitochondria causes the death of concerned pathogen (Kulda,
1999). Trimethoprim-sulfamethoxazole (TMP-SMX) (82, 83)
is used as the second line medication when the first line
treatment by metronidazole (14) does not work (Ok et al.,
1999). Other compounds being occasionally used include
pentamidine (84), iodochlorhydroxyquin (85), furazolidone
(48), iodoquinol (86), tinidazole (15), nitazoxanide (52), and
emetine (87) (Moghaddam et al., 2005; Sohail and Fischer,
2005). Paramomycin (51), a broad spectrum aminoglycoside
antibiotic has exhibited superior performance in comparison to
metronidazole (14). Therefore, it can act as the therapeutic agent
for B. hominis infections (Van Hellemond et al., 2013).
The mechanism of action of several drugs, included
metronidazole, have been studied and found linked to the
induction of programmed cell death in the parasite, when treated
with a surface reactive cytotoxic monoclonal antibody (MAb
1D5). The central vacuole of B. hominis grown in normal
physiological conditions may contain lipid granules or electron-
dense particles. This central vacuole is used for programmed cell
death (PCD) process and it acts as a repository where apoptotic
bodies are stored before being released into the extracellular
space. Central vacuole is potent target for apoptosis (Nasirudeen
et al., 2001, 2004).
ISOSPORA BELLI
Isosporiasis is human intestinal disease caused by the parasite
I. belli. It is most commonly observed in Africa, Asia and
South America. The currently used drugs against this infection
is combination of trimethoprim (82) and sulfamethoxazole (83)
(Goodgame, 2003; Hunter et al., 2004). The pyrimethamine (88)
and sulfadiazine (89) also cure the diarrheal disease caused
by I. Belli (Ferguson et al., 1980; Ebrahimzadeh and Bottone,
1996). Macrolide antibiotics like sirimamycin proved to be
effective when pyrimethamine-sulfadoxine (88, 90) fails to cure
the intestinal infection by I. belli specifically in AIDS patients
(Ferguson et al., 1980). Similarly, roxithromycin (91) is also
observed to be effective for chronic I. belli induced diarrhea
when TMP-SMX (82, 83) or pyrimethamine (88) treatments
become inadequate (Musey et al., 1988). It has been reported
that metronidazole (14), tinidazole (15), quinacrine (50), and
furazolidone (48) also cure the I. belli induced diarrhea but to
lesser extent. However, the treatment with metronidazole is more
efficient than tinidazole (15), quinacrine (50), and furazolidone
(48) (Trier et al., 1974; Syrkis et al., 1975; Butler and De
Boer, 1981; Weiss et al., 1988). The antimalarial compounds,
primaquine phosphate (92) and chloroquine phosphate (93) may
be helpful in immunocompetent patients with persistent I. belli
infection (Trier et al., 1974). The synthesis of more potent drugs
and tracing the valuable targets is the important area of research
for I. belli intestinal infection.
CYCLOSPORA CAYETANENSIS
Cyclosporiasis is the gastrointestinal illness caused by the
microscopic parasite C. cayetanensis. The extent of illness varies
based on age, condition of the host and size of the infectious dose
(Goodgame, 2003). Trimethoprim–sulfamethoxazole (82, 83)
was at first used to treat cyclosporiasis in immunocompetent and
immunocompromised patients (Madico et al., 1993; Guerrant
et al., 2001). However, the patients who are allergic to sulpha
drugs, the ciprofloxacin (94) or trimethoprim (82) is prescribed
(Verdier et al., 2000). Nitazoxanide (52) had no severe side
effects and was tolerated effectively and can be better option for
intestinal infection caused by C. cayetanensis (Diaz et al., 2003).
The development of effective drugs and the quest of essential
targets are of prime importance to treat cyclosporiasis.
CONCLUSION
Drug development for parasite-induced diarrheal disease is in
progress. There is a pressing need for the identification of
compounds which are efficacious in in vivo animal studies
and can be subjected to clinical trials. Drug development for
C. parvum is particularly challenging because of the difficulty
of in vitro screening. Maximum effort should be directed
toward new compounds to treat cryptosporidiosis because of
the limited availability of effective drugs. Resistance to the
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current drugs, metronidazole, paromomycin, and nitazoxanide
is a major concern. A major research focus on key biochemical
pathways, identification of essential targets, better assay methods,
and in vivo testing are urgently needed to identify new
chemotherapeutic agents for parasite-induced diarrheal disease.
As per our contemplated study, there is a need for the
determination of mechanism of action of the synthesized
compounds against E. histolytica andG. lamblia. The synthesized
heterocyclic scaffolds bearing different substituents that have
been found to be active in vivo studies against the parasites
causing diarrhea, can be further explored as future drug
candidates with higher efficacy, resistance effectiveness, and
lesser side effects.
The bold numbers in braces refer to the chemical structures of
the respective compounds (see Supplementary Material).
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